Salicylic acid analogues as chemical exchange saturation transfer MRI contrast agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial infusion

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 7, 2016, Pages 1186-1194

  Song, Xiaolei ^a,b   Walczak, Piotr ^a,b,c   He, Xiaowei ^a,d   Yang, Xing ^a   Pearl, Monica ^a   Bulte, Jeff W M ^a,b   Pomper, Martin G ^a   McMahon, Michael T ^a,b   Janowski, Mirosław ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^d NORTHWEST UNIVERSITY   (China)

^e MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

BBB opening; CEST MRI; perfusion territory; Salicylic acid analogues

Indexed keywords

2,5 DIHYDROXYTEREPHTHALIC ACID; BETA RESORCYLIC ACID; FERUMOXYTOL; GADOLINIUM PENTETATE MEGLUMINE; MANNITOL; SALICYLATE SODIUM; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; 2,5-DIHYDROXYTEREPHTHALIC ACID; BETA-RESORCYLIC ACID; CONTRAST MEDIUM; HYDROXYBENZOIC ACID DERIVATIVE; PHTHALIC ACID DERIVATIVE; SALICYLIC ACID; SOLUTION AND SOLUBILITY;

ANIMAL EXPERIMENT; ARTERY CATHETER; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CHEMICAL EXCHANGE SATURATION TRANSFER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HEMISPHERE; HYPEROSMOLALITY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; CHEMISTRY; DIAGNOSTIC IMAGING; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; INTRAARTERIAL DRUG ADMINISTRATION; METABOLISM; OSMOLARITY; PERFUSION; PROCEDURES; SCINTIGRAPHY; SOLUTION AND SOLUBILITY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CONTRAST MEDIA; HYDROXYBENZOATES; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; OSMOLAR CONCENTRATION; PERFUSION; PERFUSION IMAGING; PHTHALIC ACIDS; RATS, SPRAGUE-DAWLEY; SALICYLIC ACID; SODIUM SALICYLATE; SOLUTIONS;

EID: 84976892880     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16637882     Document Type: Article

References (35)

1. Woodworth GF, Dunn GP, Nance EA, et al. Emerging insights into barriers to effective brain tumor therapeutics. Frontier Oncol 2014; 4: 126
2. On NH, Mitchell R, Savant SD, et al. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J Neuro-Oncol 2013; 111: 133-143
3. Riina HA, Fraser JF, Fralin S, et al. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Experiment Therapeut Oncol 2009; 8: 145-150
4. Neuwelt EA, Barnett PA, Hellstrom I, et al. Delivery of melanoma-Associated immunoglobulin monoclonal antibody, and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988; 48: 4725-4729
5. Roman-Goldstein S, Mitchell P, Crossen JR, et al. MR, and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. Am J Neuroradiol 1995; 16: 543-553
6. Joshi S, Reif R, Wang M, et al. Intra-Arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study. Neurosurgery 2011; 69: 706-712; discussion 712
7. Bulte JW, De Jonge MW, Kamman RL, et al. Dextranmagnetite particles: contrast-enhanced MRI of bloodbrain barrier disruption in a rat model. Magnet Reson Med: Official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 1992; 23: 215-223
8. Neuwelt EA, Weissleder R, Nilaver G, et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 1994; 34: 777-784
9. Janowski M, Walczak P, and Pearl M. Predicting, and optimizing the territory of blood-brain barrier opening by superselective intra-Arterial cerebral infusion under dynamic susceptibility contrast MRI guidance. J Cerebral Blood Flow Metab 2016; 36: 569-575
10. Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis, and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013; 23: 307-318
11. Thomsen HS, Morcos SK, and Dawson P. Is there a causal relation between the administration of gadolinium based contrast media, and the development of nephrogenic systemic fibrosis (NSF)?. Clin Radiol 2006; 61: 905-906
12. Rydahl C, Thomsen HS, and Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadoliniumcontaining magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-144
13. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrastenhanced MR imaging. Radiology 2015; 275: 772-782
14. Gadolinium-based contrast agents forMagnetic Resonance Imaging (MRI): Drug safety communication - FDA evaluating the risk of brain deposits with repeated use http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm456012.htm
15. Blanchette M, Tremblay L, Lepage M, et al. Impact of drug size on brain tumor, and brain parenchyma delivery after a blood-brain barrier disruption. J Cereb Blood Flow Metab: Official journal of the International Society of Cerebral Blood Flow, and Metabolism 2014; 34: 820-826
16. Aime S, Carrera C, Delli Castelli D, et al. Tunable imaging of cells labeled with MRI-PARACEST agents. Angew Chem Int Ed 2005; 44: 1813-1815
17. Zhou J, Tryggestad E, Wen Z, et al. Differentiation between glioma, and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins, and peptides. Nat Med 2011; 17: 130-134
18. Song X, Airan RD, Arifin DR, et al. Label-free in vivo molecular imaging of underglycosylated mucin-1 expression in tumour cells. Nat Commun 2015; 6: 6719
19. Sagiyama K, Mashimo T, Togao O, et al. In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma. Proc Natl Acad Sci U S A 2014; 111: 4542-4547
20. Ling W, Regatte RR, Navon G, et al. Assessment of glycosaminoglycan concentration in vivo by chemical exchange-dependent saturation transfer (gagCEST). Proc Natl Acad Sci U S A 2008; 105: 2266-2270
21. Cai K, Singh A, Poptani H, et al. CEST signal at 2ppm (CEST@2ppm) from Z-spectral fitting correlates with creatine distribution in brain tumor. NMR Biomed 2015; 28: 1-8
22. Chen LQ, Howison CM, Jeffery JJ, et al. Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI. Magnet Reson Med: Official journal of the Society of Magnetic Resonance in Medicine /Society of Magnetic Resonance in Medicine 2014; 72: 1408-1417
23. Chan KW, Liu G, Song X, et al. MRI-detectable pH nanosensors incorporated into hydrogels for in vivo sensing of transplanted-cell viability. Nat Mater 2013; 12: 268-275
24. Farrar CT, Buhrman JS, Liu G, et al. Establishing the lysine-rich protein CEST reporter gene as a CEST MR imaging detector for oncolytic virotherapy. Radiology 2015; 275: 746-754
25. Song X, Yang X, Ray Banerjee S, et al. Anthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular-bond shifted hydrogen. Contrast Media Mol Imag 2015; 10: 74-80
26. Yang X, Song X, Li Y, et al. Salicylic acid, and analogues as diaCEST MRI contrast agents with highly shifted exchangeable proton frequencies. Angewandte Chemie 2013; 52: 8116-8119
27. Song X, Xu J, Xia S, et al. Multi-echo length, and offset VARied saturation (MeLOVARS) method for improved CEST imaging. Magnet Reson Med: Official journal of the Society of Magnetic Resonance in Medicine /Society of Magnetic Resonance in Medicine 2015; 73: 488-496
28. Song X, Gilad AA, Joel S, et al. CEST phase mapping using a length, and offset varied saturation (LOVARS) scheme. Magnet Reson Med: Official journal of the Society of Magnetic Resonance in Medicine /Society of Magnetic Resonance in Medicine 2012; 68: 1074-1086
29. Grady RW, Graziano JH, Akers HA, et al. The development of new iron-chelating drugs. J Pharmacol Experiment Therapeut 1976; 196: 478-485
30. Hill AP, and Young RJ. Getting physical in drug discovery: a contemporary perspective on solubility, and hydrophobicity. Drug Discov Today 2010; 15: 648-655
31. Terasaki T, Takakuwa S, Moritani S, et al. Transport of monocarboxylic acids at the blood-brain barrier - studies with monolayers of primary cultured bovine brain capillary endothelial-cells. J Pharmacol Exp Ther 1991; 258: 932-937
32. Ryder HW, Shaver M, and Ferris EB. Salicylism accompanied by respiratory alkalosis, and toxic encephalopathy - report of a fatal case. N Engl J Med 1945; 232: 617-621
33. Pickard JD, Rose JE, Shaw MD, et al. The effect of sodium salicylate on cerebral blood flow, and metabolism. Br J Pharmacol 1980; 68: 407-411
34. Xu X, Chan KW, Knutsson L, et al. Dynamic glucose enhanced (DGE) MRI for combined imaging of bloodbrain barrier break down, and increased blood volume in brain cancer. Magnet Reson Med: Official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 2015; 74: 1556-1563
35. Yang X, Yadav NN, Song X, et al. Tuning phenols with Intra-Molecular bond Shifted HYdrogens (IM-SHY) as diaCEST MRI contrast agents. Chemistry 2014; 20: 15824-15832